EZH2 and lymphoma: Across a variety of lymphoma cell lines including Hodgkin's, non-Hodgkin's, and Burkitt lymphoma, DLBCL cells remained the most sensitive to EZH2 inhibition by GSK126, with seven out of 18 displaying sub-micromolar growth IC50s (28–861 nM) including both cytostatic and cytotoxic responses.